Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell CarcinomaJames J. Hsieh, Robert J. Motzer, S. Duygu Selçuklu et al.|European Urology|2016Cited by 204
Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in <i>PBRM1</i> and <i>BAP1</i> with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy.Martin H. Voss, A. Ari Hakimi, Fengshen Kuo et al.|Journal of Clinical Oncology|2017Cited by 28
Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3.James J. Hsieh, Robert J. Motzer, David Chen et al.|Journal of Clinical Oncology|2015Cited by 26